89bio Logo (full size)
89bio Logo icon/symbol
89bio Logo (full size) on a dark background
89bio Logo icon/symbol on a dark background
About 89bio
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
July 6th, 2024
